Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1B Trial of ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

Next Previous
X
Search
Trial Profile

Phase 1B Trial of ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegargiminase (Primary) ; Temozolomide (Primary) ; Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Acronyms GBM
  • Sponsors Polaris Pharmaceuticals

    • Most Recent Events

    • 29 Sep 2022 Planned End Date changed from 31 Jul 2022 to 30 May 2027.
    • 29 Sep 2022 Planned primary completion date changed from 31 Jul 2022 to 28 Feb 2027.
    • 07 Jun 2022 Results (n=23) assessing major adverse events from cohort 1 and cohort 2 of this trial presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top